Drug Combination Details
| General Information of the Combination (ID: C81147) | |||||
|---|---|---|---|---|---|
| Name | Sulforaphane NP Info | + | Cisplatin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [1] | ||
|
Peritoneal cancer
[ICD-11: 2C51]
|
Investigative | [2] | |||
|
Epidermal squamous cell carcinoma
[ICD-11: 2E64]
|
Investigative | [3] | |||
|
Ovarian cancer
[ICD-11: 2C73]
|
Investigative | [4] | |||
|
Breast cancer
[ICD-11: 2C60]
|
Investigative | [5] | |||
| Click to Show/Hide the Whole Disease Information of This Combination | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [5] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | 44472 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | SIRT1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | SIRT1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | ||
| MDA-MB-468 | CVCL_0419 | Breast adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
CIS when supplemented with SFN, inhibits metastasis and stemness potential of TNBC cells by down regulating SIRTs-mediated EMT cascade. | |||||
| Experiment 2 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | NCI-H28 | CVCL_1555 | Pleural sarcomatoid mesothelioma | Homo sapiens | ||
| MeT-5A | CVCL_3749 | Healthy | Homo sapiens | |||
| Experimental
Result(s) |
Pro-oxidant activity of sulforaphane and cisplatin potentiates apoptosis and simultaneously promotes autophagy in malignant mesothelioma cells. | |||||
| Experiment 3 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PARP1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | XIAP | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HuCC-T1 | CVCL_0324 | Intrahepatic cholangiocarcinoma | Homo sapiens | ||
| TFK-1 | CVCL_2214 | Cholangiocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Sulforaphane sensitizes human cholangiocarcinoma to cisplatin via the downregulation of anti-apoptotic proteins. | |||||
| Experiment 4 Reporting the Effect of This Combination | [3] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | SCC-13 | CVCL_4029 | Skin squamous cell carcinoma | Homo sapiens | ||
| HaCaT | CVCL_0038 | Healthy | Homo sapiens | |||
| Experimental
Result(s) |
Combined therapy with sulforaphane and cisplatin is efficient in suppressing tumor formation. | |||||
| Experiment 5 Reporting the Effect of This Combination | [4] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | microRNA 30a | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | A2780 | CVCL_0134 | Ovarian endometrioid adenocarcinoma | Homo sapiens | ||
| IGROV-1 | CVCL_1304 | Ovarian endometrioid adenocarcinoma | Homo sapiens | |||
| In-vivo Model | A2780/CP70 and IGROV1-R10 cells (4 * 106) were injected into nude mice sub cutaneously. | |||||
| Experimental
Result(s) |
SFN enhances cisplatin sensitivity of ovarian carcinoma cells through up-regulating miR-30a-3p to induce DNA damage and accumulation of intracellular cisplatin. | |||||
